ACM Global appoints Asia Pacific general manager

He will initially build ACM Global team in India

ACM Global Central Laboratory has announced the newest member of its Clinical Trials team, Nandan Rao as general manager, Asia Pacific. He will be located in Mumbai, India and initially will have oversight of trials conducted with ACM Global’s partner lab in the region.

Rao will also be building the ACM Global infrastructure and team throughout Asia Pacific.

Rao was formerly general manager of SRL, the largest clinical reference laboratory network in India and Southeast Asia, where he built the firm’s clinical trials operations.

‘Since establishing its presence in India in 2006, ACM has become a global leader in the central lab arena,’ said Elena Logan, VP of Clinical Trials at ACM Global Central Lab.

‘Nandan’s expertise in building a central lab group in this region will be of significant value to our organisation as we continue to expand ACM Global wholly owned locations.’

You may also like

Regulatory

ACM Global relocates European hq to expanded lab facilities

Moves into a new, state-of-the-art facility in York, UK
Regulatory

ACM Global Central Laboratory establishes Mumbai subsidiary

Operational facility is dedicated to managing clinical trials testing in India and study support in Asia Pacific
Manufacturing

Redefining QP training for today’s professionals

How NSF is making specialist learning more flexible and accessible
Manufacturing

NSF’s QP training program combines technical skill with personalised guidance

A mentoring-led approach supporting delegates through every stage of the QP journey
Finance

HitGen secures Gates Foundation funding to advance drug discovery for tuberculosis, malaria and contraception

HitGen will use its DNA-encoded library platform to identify new drug leads for TB, malaria and non-hormonal contraception. The new Gates Foundation agreement expands on earlier collaboration to accelerate treatments for underserved diseases
Finance

Almac announces multi-million-pound investment in Singapore

Almac Group has announced a multi-million-pound investment to expand its facility in Singapore, as the company marks ten years of operations in the country
Regulatory

Poolbeg Pharma granted European patent for flu drug

POLB 001 targets the body's inflammation machinery and prevents dangerous immune overreactions. The drug could also be used in the treatment of other inflammation-based diseases, such as Cytokine Release Syndrome
Subscribe now